Organovo Holdings (Seite 55)

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.393.658 von PhaseDrei am 02.10.16 15:12:45

Hallo,

allen, die das aktuelle Podcast-Interview mit Keith Murphy noch nicht kennen sei es wärmstens empfohlen
Breakthroughs Are Just the Beginning: How a 3D Bioprinting Pioneer Creates a Market

....In this episode of The Uncoventionals, we talk with Organovo CEO Keith Murphy about bioprinting and its big implications for human health. We’ll also discuss how they tell their story, find early application markets, and convince pharma customers to try the platform. Turns out that WHO you talk to first is critical. The key is connecting with buyers that are, as Keith says, “alive to new possibilities.” Find out how Organovo is enlisting the change agents — or as we like to call them "the crazies” — to bring a breakthrough platform to life. .

es ist über den aufgeführten link auch als Abschrift abrufbar:

http://www.agencypja.com/the-unconventionals/breakthroughs-a…

hier der interessante zweite Teil in denen KM auf die Vermarktung der revolutionären tests eingeht!
Michael:
Early in my career, I was helping a startup market a new diabetes test. It was cool technology. It was some pretty simple monitoring equipment that would enable doctors to get earlier indications about diabetic neuropathy. I was a young and enthusiastic. I was doing some field research getting feedback on the technology. This one doctor, an endocrinologist, heard me out and brought me over the closet. He opened the door and it was filled with computer monitors, cords, and a bunch of random medical devices that had all been tried and discarded over the years, all of which I’d assume prided some advantage over current practice. I started out thinking this monitor was a no-brainer, but all of these products represented change and to an audience of experts, whether they're doctors or scientists, changing a practice or workflow is hard and fraught with risk.

Keith:
I think in marketing, an awareness of these is always a big problem. Actually I go back to an anecdote from when I was at Amgen. Amgen had developed drugs that were transformative in cancer care and I was on, I was an engineer at the time and I was on a business trip with another engineer whose mother had a disease that Amgen had a drug for. He and she both lived within miles of Amgen and the drug had been on the market for three years and her doctor wasn’t aware of the drug and wasn’t prescribing the drug for his mother, despite the fact that they were so close to Amgen headquarters.


That’s why marketing is so important. Sometimes, it gets a bad name but if people aren’t aware of the opportunity to benefit from something, you can't have the impact. Our market is like any other market. It has an adoption curve and you have to work through that, you have to educate the customer and that takes a long time. One thing-

Michael:
What are the obstacles? Is it that you just can’t get people paying attention because they're so busy and they're minds are so crowded with information? Is it that or is it they, "Yeah, we know about 3-D bio printing. That doesn’t work for our models"? Where is it?

Keith:
Let’s start with the customer that we're talking about. We're talking about a scientific customer within Pharma who’s going to choose to use our liver tissue to predict drug safety. Let's talk about that customer. They're a trained scientist and they’re very smart and know their space very well but that training can sometimes work in your disfavor too because just like in any market, you're going to have early adopters who get their head around new concepts faster and people who rely on their training more and wait for what I’ll call "pure referencing" to switch, so they're not going to switch until three or four people they know are using it and that gives you a market adoption curve.


The biggest normal hurdle is just level of data available and how quickly you can convince someone. We constantly invest in new, more and newer data to show and prove this so we had a big publication in July that actually showed the benefits of this over 2-D cells and that’s really critical, getting those peer-reviewed, published journal articles.

Michael:
Because that's the first obstacle, right? "Show me the data."

Keith:
Yeah.

Michael:
And if you don't have data that’s applicable, "Come back later, I suppose."

Keith:
There are particular problems that we run into too. One is that some of the scientists have been told stories about new models in the past. A decade ago, there were some newer models that were 3-D like but didn’t have the kind of data that we have and these folks feel like they were misled about the potential of those technologies, they invested in them, and they didn’t work as well as ours is working now. We have a higher hurdle with some of those customers and then I think another thing, I'll give an anecdote, we have new capabilities that these folks can't even get their heads around until they see it in action. The ability to have these tissues live for a number of weeks in the lab, when we did our initial market testing, we couldn’t even get good answers out of the potential customers because they couldn’t get their heads around that-

Michael:
Or disbelieved it.

Keith:
Or they didn't believe it, right. It's just not something, they’re used to having a two or three day study with liver cells on a dish, they don’t know how they would use a two-week or a one-month study. They know it’s useful but they haven’t thought it through yet and so those kind of problems really come up and it's just a normal learning process for both sides. We're working through all that and getting greater and greater adoption.

Michael:
All of what Keith is talking about will feel familiar to anyone who's marketing an innovation that outstrips what people know how to apply in their lives. Helping them to accept a new way is hard work. It’s about gathering data, finding early proof and prototypes, anticipating and overcoming particular points of fear, uncertainty and doubt, there's no magic but Organovo also realized something that many companies get wrong. They were targeting change agents.


Turns out who you talk to first, who you convince to get on board early, is critical. We call them the crazies, the people in the market that are looking for new and better ways that share your vision for where the market is heading. Back to my diabetes example, that crusty old endocrinologist, he was the wrong guy. He was never going to adopt something new.

Keith:
Yeah. I think there’s people who are maybe 20 to 30% of any market and in our case, that’s very much true, where they're more alive to new possibilities. They want to explore. They want to do the best work for their company and they’re trying to think through how they can use something new even before it’s well-proven. Those are the people that we thought we could get. When we launched, we found that to be true. As we’ve added more data over time, we find that we're penetrating with more and more people.

Michael:
How do you reach those 20 to 30% differently? You don’t have as much data. Is it making the mission, the broader mission, a little bit more front and center with them? Is it, what is it?

Keith:
I think part of the argument is just asking them to see the totality of the data set and kind of say, "I can get my head around where this is headed," before it’s completely proven. A lot of scientists say, "Looks good, but let me see more," but these early adopters kind of say, "Oh, I see where this is heading and I want to do a couple tests myself and then I can buy in."

Michael:
They can start to imagine if all these things are true, what might be possible.

Keith:
That’s right, what might be possible.

Michael:
The trick is how to find these people, the crazies, change agents, early adopters. It’s not about excluding anyone. Organovo's target is pretty focused and they can and do make their information available to every scientist who might find it relevant, but the more important effort is identifying those people who are willing to engage and go deeper from the very start. Organovo finds these people at events and has gotten good at sniffing them out in clients and partners. One common trait is that for change agents, adopting and proving new technology is an important driver of their professional success.

Keith:
One of the things we’ve done is we don’t, we do to some degree try and identify who those are, but we cast a broad net in our marketing and in our efforts to find people because everybody needs to know about it before they’ll adopt and so it’s just that you can't always expect the first touch to result in a contract with everyone but what we've found is that across the spectrum of these scientists even well beyond the early adopters, we found no one saying, "No, I don’t want to use that."


We found people saying, "Oh, that’s really compelling and interesting, but I need to see more before I buy," so that’s really validating too that you’re on the right track and they’re just, you get a sense from them of what data they want to see, you work to build that, and then you get additional folks over time.

Michael:
I imagine those early adopters were critical in landing your current clients, your current pilots with Pharma companies.

Keith:
Yeah and especially the fact that many of them have now come out and start to show their use of our platform and so in March of this year, we had the first open reports from some of our customers where they went to the Society of toxicology annual meeting and showed their work. Bristol-Myers Squibb and Astellas both showed that they were working with it, reported positively on their results. They get a lot of inquiries from other Pharma scientists and that starts to drive interest.

Michael:
Do you ever see these people, in Bristol-Myers or any other early clients, do you see these early adopters, do they do some of the work for you within their companies? Because they're not making decisions by themselves to bring this in.

Keith:
That’s right. They do do some of the work not only within their companies, but broadly speaking. One thing that is nice about our customer base and these early adopters and these change agents is, you're right to call them change agents because they're change agents within their company, they're change agents across the industry. A lot of them, one of the compelling drivers is to be known as and seen as a leader in the science and so for them to come out and talk about this, they’re doing two things. Obviously, they're helping us, but that’s an important career step for them is to be seen as an early adopter of a new compelling technology and demonstrating its usefulness. To be frank, they can establish how this should be used across the industry. They're really on the forefront of doing that so they're trailblazers.

Michael:
Trailblazers, absolutely and I think that not only they're alive to possibilities which is a phrase that you use, which I really like, but they also want to make their mark, I think.

Keith:
Yeah, that’s right. That’s exactly right. In a scientific context, that’s really compelling for them. They want to publish. They want to be out there because they want to be known. They want to make their mark.

Michael:
One of the behaviors of unconventional companies is they bring new perspectives and expertise to old problems. One way to think about this is the beginner’s mind. People who are new to a problem will consider many possibilities. To the expert, there’s only one path forward. Organovo brought together engineers and cell biologists in a way the market hadn’t done before. Keith talks about how some of the research methods for cell biologist haven't changed for 50 years.


It took physics and a range of engineering disciplines to think beyond the cell to the structure of the tissue and as we’ve said, this is the transformative insight of Organovo. Creating an environment where these experts can collaborate productively is critical to the company's success, but it isn't easy.

Keith:
One of the difficulties is that these, everyone is still focused on what they were trained in as a discipline and so we're kind of crossing over these disciplines to have folks work together but sometimes your [blindered 00:27:13] still by your particular field. I think we’ve done a good job though of developing a system where really what we’ve got is a tool. It’s a platform that gives scientists a tool to do new things in biology and you can bring in an expert in a given tissue type and it has to be someone who has a really good understanding of spatial concepts and is not so tied just to the molecular biology and the chemistry, the biochemistry. They have to be able to think in a multidimensional way but once they can do that, they can partner with the systems biology folks, the platform engineers who run the bio printer and get to really compelling results.

Michael:
I think that's a good story because it feels like scientists and engineers, they're expert. They've spent a lot of time learning this and honing this. It’s hard not to be expert in a room, right?

Keith:
Oh, yeah. I think we tend to find people who work in a team effort to solve problems but science is a field where yeah, a lot of times expertise is valued and you want to be seen as the top person and an expert and you have to kind of sublimate that to the larger team goal. That’s definitely something that we’ve had to hire to, to make sure that we can get to the team goals.

Michael:
So there's certain people who are willing not to be the smartest guy in the room?

Keith:
Just, I think people all have to pull together and recognize that they all come out a lot smarter and reach their goals. If they were left to their own individual devices, they may not get there.

Michael:
We often talk about the need for companies, particularly innovation-driven B2B companies to connect to a larger movement not just pursue a technology or market. It’s the larger mission. The bigger set of problems you’re trying to solve that have the power to capture imaginations of buyers and investors, employees, the general public even. Organovo's mission and larger purpose is right there. In fact, their challenge is almost the opposite. The popular imagination goes right to printing hearts and lungs. Organovo's job is to not overpromise, to reel in imaginations, to make sure every application is backed up by data and proven.


Theranos and their spectacular rise and fall is perhaps the most dramatic example of the risks of hyping expectations, but while Organovo has to temper expectations, there’s a balance there. Its job is also to communicate that what is possible today is still transformative and exciting.

Keith:
I'm actually really proud of the way we’ve dealt with that. It’s possible to easily over-hype what can be done in this space and you have to capture the imagination, you very rapidly get attention for some of the things that we're working on, and we just strive to balance it quickly with the reality. When we were talking earlier, I'm always careful to point out that we're not talking about full organs that we're moving forward. That’s a ways off. We're talking about organ patches and we’ve always taken that tack.


In fact, when we did our own analysis of our cultural values, credibility really rose to the top and is one of our key cultural values. It’s internal, it’s external but you don’t get anywhere by over-hyping and over-promising things because, well you might get somewhere in the short term, but it doesn’t benefit you in the long run. One of the things that we hear consistently from our Pharma partners and our other partners and customers is that's something they really value about us. When our scientists come into the room, when our executives come into the room, we're talking very credibly about what we can and what we can’t do very openly and we make that a partnership and they can trust in what we're saying.

Michael:
It occurs to me maybe part of it is you’re shaping the conversation because we don’t know how to think about it, and so we go to what we can imagine, which is seeing a beating heart at the end of that printer.

Keith:
Yeah.

Michael:
But it doesn’t have to be that. It doesn’t have to be a fully printed liver or kidney. A liver or kidney patch is amazing and would be transformative to human health, right?

Keith:
That’s absolutely right. As business people, that’s our challenge. We have to find the thing that works. It’s like, when you’re creating a product for the first time, you have to know when it’s good enough to launch. You can't keep striving for perfection. You need to find what you can get to in a reasonable time frame, get it out there, and then you get the double benefit. You get the benefit that you're bringing to patients and then the benefit to the revenues that start to come in as well.

Michael:
If this doesn’t, if this doesn’t take off, and I’m not talking just to Orgonovo, but 3-D bio printing, if it doesn’t really meet its promise, what will stop it do you think? Is it the science, scientific limitations? Is it the story?

Keith:
I think that if the longer-term vision of organs and tissues for transplant doesn’t play out the way we hope, it’ll just take longer to come up with the right tissue engineering methods and bio printing may need complementary methods to move things forward. It may not move as fast as we’d like. I’d be surprised if we don’t have some broad impact. It’s just a matter of, I think about it as finding the right avenues. It’s not necessarily always the thing that you’re working on that ends up being the big success. You work in a number of areas and you find success with a platform technology.

Michael:
Thanks to Keith and the team at Organovo for their time and hospitality and thanks to Peggy at Little [inaudible 00:32:35] communications for making this all happen. Next time on The Unconventionals, we'll be talking to Mark Rosenthal who heads up Google's healthcare practice. Join us to find out how Google is driving innovation in the industry.
.........


Fazit: the future is bright - proud to be a shareholder!

Gruß, Phase

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.393.610 von PhaseDrei am 02.10.16 15:03:40

Hallo,

für alle, die die fachliche Voraussetzungen mitbringen und das Interesse haben, tiefer in die Nieren-Thematik einzutauchen, hier das webinar:

http://organovo.com/webinar3/

für alle anderen eine schöne Zusammenfassung von Dr. Z aus dem yahoo board:

drzzzzzzz • Sep 30, 2016 9:56 PM Flag

5
users liked this posts

users disliked this posts
0
Reply


Just back from 3D Tissue Models, San Diego (XV)
.

The following are highlights from two careful listens to the outstanding webinar on the ExVive Kidney presented Thursday morning:
Shelby King, Ph.D, Cellular and Molecular Biology
Senior Research Scientist, Organovo

o 20 minutes to print a 24-well plate, with ultimate tissue size 3mm x 3mm x 100 microns
o Model shows renal transport, excretion, toxicity and fibrosis
o Bioprinting is pivotal to producing the flat, laminar functional reproduction of the proximal tubule. Co-culture models without attention to spatial arrangement yield hyperactive renal fibroblasts with heavy deposition of collagen, tissue contraction and loss of function
o Abundant microvascular networks support the tissue functional longevity for almost 8!! weeks
o Collagen-IV rich basement membrane between epithelium and interstitium develops after printing, astonishing in vivo-like interplay between the cell layers
o In vivo relevant barrier function
o Key renal transporters are expressed at appropriate locations
o SGLT2 glucose transporter is functional
o P-gp efflux transporter (critical in toxicities) is functional
o Dose-dependent cisplatin toxicity shown by both biomarkers and histology with compensatory epithelial proliferative response in higher doses
o New histology with nephrotoxicant amphotericin B showing very elegantly the selective destruction of the epithelial layer, leaving the interstitial layer intact
o Lengthy Q&A--lots of attendees--which Shelby fielded beautifully and answered fully
o Ongoing studies looking at drug-induced fibrosis, modeling diabetic nephropathy

The early data is comprehensive and very, very strong. These in vitro capabilities are absolutely unprecedented. It is no wonder why a dozen pharmas eagerly awaited the commercial release. And looking only at the highly manipulated share price, one would never realize what is actually going on.

Addition to the NASDAQ Biotechnology Index begins next week!

Cheers,
Z Less

Sentiment: Strong Buy

Fazit: the future is bright - proud to be a shareholder!

Gruß, Phase

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.393.199 von Schaeffi am 02.10.16 13:01:19

Hallo,

zur Erinnerung eine Meldung vom 13.01.2016

Organovo Subsidiary Samsara Sciences Launches Commercial Operations
http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-newsArt…

Samsara wurde primär gegründet zur kostengünstigen Deckung des nötigen Eigenbedarfs an Zellen (zunächst Leberzellen) und zweitens zum Zwecke der Veräußerung von Zellen an externe Kunden, was längerfristig eine weitere Einnahmequelle bedeuten dürfte.

nun...
lange Zeit waren auf der Samsara-Webseite keine Aktivitäten zu erkennen, obwohl ich mir sicher war, dass Organovo hinter den Kulissen fieberhaft am Aufbau arbeitete.

jetzt, nach dem Aufbau des Vertriebsnetzes bei Organovo, den dadurch bedingten deutlichen Anstieg des Kundeninteresses und einem damit einhergehenden erhöhten Auftragsvolumen scheint man bei Samsara mit dem Aufbau einer differenzierten Zellbank ein gutes Stück vorangekommen zu sein!

22 Leberzellproben zu verschiedenen Krankheitsbildern und unterschiedlichem Grad an Leberverfettung!
http://www.samsarasciences.com/stellate-cells/

übrigens:
die Rubrik für Nierenzellen ist auf der Startseite auch schon angelegt - bin mir sehr sicher, dass wir auch hier bald Inhalte präsentiert bekommen.

Die Samsara-Entwicklung - gut durchdacht, vorausschauend und rechtzeitig in die Wege geleitet- ist für mich einmal mehr ein klarer Beweis für das erstklassige Management Organovos.
Man überlässt nichts dem Zufall. Wir Aktionäre wissen sicher nur recht wenig von den hinter den Kulissen sich abspielenden tatsächlichen Entwicklungsaktivitäten. Man ist sicher längst dabei die entscheidenden Weichen für eine weitere erfolgreiche Expansionsphase bei Organovo zu stellen.

Fazit: So macht es Freude!

die Ampeln stehen aus meiner Sicht klar auf grün - der Kurs ist für mich in dieser noch frühen Phase wirklich Nebensache!

Gruß, Phase

[Schaeffi]

Antwort auf Beitrag Nr.: 53.351.418 von Schaeffi am 26.09.16 20:23:08

nachkaufen??

gewisse seriöse quellen vermuten einen Kursrückgang

click-->https://unicornbay.com/t/ONVO.US?utm_medium=tweet&utm_campai…

könnte sein, falls der Up Kanal der grad bei ca. 2,75USD verläuft von oben durchbrochen wird.
dann sehen wir ggfs. noch mal 3USD.

interessant Punkte die zuletzt augenfällig wurden:
-MK ist immer noch 1/3 bis 1/2 von d. Rechtskosten bei Rücknahme eines zugelassenen Medi vom Markt siehe z.B. Troglitazone (auch Rezulin, Resulin, Romozin, Noscal)

und

-FDA könnte Onvo 3D Tissue als standard Test fordern, fördern, verlangen, befürworten,....


es bleibt spannend
S.

[Schaeffi]

Kurs pendelt um die 4USD-->https://www.tradingview.com/x/nNcOj2nc/
und läuft an die Unterkante des Up-Chanel.

Entscheidung baldigst - nächste Woche ?

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.313.963 von PhaseDrei am 20.09.16 19:44:54

Hallo,

Da wurde mein post nur bruchstückhaft übertragen

Hier die Links

http://organovo.com/about/news/upcoming-events/

Und das hier ist besonders interessant

Bio Japan 2016
Man schau sich nur die Dimensionen an
8000 Meetings, 15000 Teilnehmer, 800 Unternehmen- das ist schon ordentlich!

http://www.ics-expo.jp/biojapan/

Übrigens
Der heutige Kursrücksetzer ist zwar nicht schön- er beunruhigt mich aber keinesfalls- findet bei sehr, sehr dünnem Volumen statt;

Fazit:
The future is bright- proud to be a shareholder!

Gruß, Phase

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.299.377 von PhaseDrei am 18.09.16 17:36:25

Hallo,

Es sieht so aus als ginge Organovo jetzt erst richtig in die Offensive

Voller Terminkalender - wird ein heißer Herbst

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.294.070 von PhaseDrei am 17.09.16 11:07:43

Hallo,

Ein ca. 30 minütige Interview mit Keith Murphy aus der Vorwoche: äußerst interessant. Besonders der zweite Teil.

http://www.agencypja.com/the-unconventionals/breakthroughs-a…

Gruß, Phase

[PhaseDrei]

Antwort auf Beitrag Nr.: 53.293.200 von Shanghai2006 am 17.09.16 03:47:06

Hallo,

Die neue Investor Presentation ist da!

Mit vielen völlig neuen und aufschlussreichen Slides.
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9M…

Besonders interessant slide Nr. 17

Man hat wohl die zeitlichen Abläufe was Kundenaufträge betrifft weiter optimieren können

- 3 Monate -

aus meiner Sicht gibt es momentan nicht die geringsten Anzeichen, die mich an einer faszinierenden Erfolgsstory Organovos in den kommenden Jahren zweifeln lassen würden.

Fazit:
Die Ampeln stehen auf grün!

The future is bright - proud to be a shareholder

Gruß, Phase

[Shanghai2006]

Guru score.

Gut und weniger gut, das muss man Alles richtig bewerten, das ist ein junges Unternehmen, mit einigen Ausgaben fuer die Entwicklung.